Alkion BioInnovations
Biotechnology Research • 
Versailles, Île-de-France, France • 11-20 Employees
Company overview
| Headquarters | Versailles, Île-de-France, France |
| Phone number | +33160878997 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biosimilars, Nutrition, Superfood, Natural Ingredients, Natural Sweeteners, Cannabinoids, Essential Oils, Biotechnologies, Agarwood, Natural Flavors, Biopharmaceutics, Terpenoids, Bioreactor 3.0, Hydroponics 3.0, Natural Additives, Secondary Metabolims, Vaccineadjuvants |
| Founded | 2017 |
| Employees | 11-20 |
| Socials |
Key Contact at Alkion BioInnovations
Sarah-Meryll Buet
Ceo / Co-Founder
Alkion BioInnovations Email Formats
Alkion BioInnovations uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@alkinnov.com), used 83.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@alkinnov.com | 83.3% |
{first initial}.{last name} | j.doe@alkinnov.com | 16.7% |
About Alkion BioInnovations
Alkion BioInnovations is a pionnier & leader in plant tissue propagation and bioengineering technologies. We have developed and patented a bioproduction platform to obtain high value ingredients (APIs, complex extracts and recombinant proteins) from plant biomass for pharmaceutical & agri-food markets on global and impactful projects. Through a carbon-neutral approach and using a minimum of resources in optimised bioreactors, our method of production is sustainable, ultra-scalable and cost-efficient. With our European partners, we develop AI robots to build the world's first industrial in-vitro bioproduction platform, that aims to be flexible and versatile. Our proprietary project is the large-scale production of the super immunity boosters "QS" for their urgent need, especially in Global South. Derived from Quillaja saponaria tree, QS enhance vaccine efficacy against infectious diseases such as Malaria, TB, HIV, Shigella etc. but also degenerative disorders and certain cancers. Our mission is to revolutionize global vaccine access by providing up to 2 billion doses p.a. at low cost and while preserving biodiversity. We work in collaboration with worldwide NGOs and universities. A secondary project is the industrial standardised production of cannabinoids, API and extracts, for the therapeutic market (CNS diseases such as Parkinson, MS, neuropathic pain). For this project Alkion owns the first historical R&D licence from French health authorities (2018). In agrifood, our biosynthesis lab focuses on a healthy sweet protein derived from an exotic plant. It has exceptional physico-chemical properties for industrial applications as healthy sugar alternative in food and pharma products. The project aims at helping farmers increase their revenues while meeting a massive demand. Alkion is laureate of I-Lab, I-Nov, Plan de Relance, the European Innovation Council Accelerator and is a finalist of Zayed Sustainability Prize in Health category (COP28).
Alkion BioInnovations revenue & valuation
| Annual revenue | $1,000,000 |
| Revenue per employee | $72,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,200,000 |
| Total funding | $5,300,000 |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Alkion BioInnovations has 9 employees across 3 departments.
Departments
Number of employees
Alkion BioInnovations Tech Stack
Discover the technologies and tools that power Alkion BioInnovations's digital infrastructure, from frameworks to analytics platforms.
Web servers
JavaScript libraries
Programming languages
Blogs
JavaScript libraries
Databases
Miscellaneous
CDN
India
Iran, Islamic Republic of
United States
Frequently asked questions
4.8
40,000 users
